Related Experiment Video
Updated: Apr 19, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
Differentially expressed proteins in human MCF-7 breast cancer cells sensitive and resistant to paclitaxel
Nela Pavlíková1, Irena Bartoňová1, Kamila Balušíková1
1Department of Cell & Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
Abstract:
Resistance of cancer cells to chemotherapeutic agents is one of the main causes of treatment failure. In order to detect proteins potentially involved in the mechanism of resistance to taxanes, we assessed differences in protein expression in MCF-7 breast cancer cells that are sensitive to paclitaxel and in the same cells with acquired resistance to paclitaxel (established in our lab). Proteins were separated using two-dimensional electrophoresis. Changes in their expression were determined and proteins with altered expression were identified using mass spectrometry. Changes in their expression were confirmed using western blot analysis. With these techniques, we found three proteins expressed differently in resistant MCF-7 cells, i.e., thyroid hormone-interacting protein 6 (TRIP6; upregulated to 650%), heat shock protein 27 (HSP27; downregulated to 50%) and cathepsin D (downregulated to 28%). Silencing of TRIP6 expression by specific siRNA leads to decreased number of grown resistant MCF-7 cells. In the present study we have pointed at some new directions in the studies of the mechanism of resistance to paclitaxel in breast cancer cells.
Insights
This study identified key proteins, including TRIP6, HSP27, and cathepsin D, involved in paclitaxel resistance in breast cancer cells. Silencing TRIP6 reduced resistant cell growth, offering new therapeutic targets.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Chemotherapeutic resistance is a major obstacle in cancer treatment.
- Understanding resistance mechanisms is crucial for developing effective therapies.
Purpose of the Study:
- To identify proteins involved in paclitaxel resistance in MCF-7 breast cancer cells.
- To investigate the role of specific proteins in acquired taxane resistance.
Main Methods:
- Two-dimensional electrophoresis for protein separation.
- Mass spectrometry for protein identification.
- Western blot analysis for expression confirmation.
- siRNA for gene silencing.
Main Results:
- Identified three differentially expressed proteins in resistant MCF-7 cells: TRIP6 (upregulated 650%), HSP27 (downregulated 50%), and cathepsin D (downregulated 28%).
- Silencing TRIP6 expression reduced the proliferation of resistant MCF-7 cells.
Conclusions:
- TRIP6, HSP27, and cathepsin D are implicated in paclitaxel resistance in breast cancer.
- TRIP6 is a potential therapeutic target for overcoming paclitaxel resistance.
Related Concept Videos
Treatment Resistant Cancers
Drugs that Stabilize Microtubules

